title: Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine.
authors.forename: Melina C
authors.initials: MC
authors.lastname: Ortigas
authors.forename: James A
authors.initials: JA
authors.lastname: Bourgeois
authors.forename: Andrea
authors.initials: A
authors.lastname: Schneider
authors.forename: John
authors.initials: J
authors.lastname: Olichney
authors.forename: Danh V
authors.initials: DV
authors.lastname: Nguyen
authors.forename: Jennifer B
authors.initials: JB
authors.lastname: Cogswell
authors.forename: Deborah A
authors.initials: DA
authors.lastname: Hall
authors.forename: Randi J
authors.initials: RJ
authors.lastname: Hagerman
mesh_terms: D000368:Aged; D001259:Ataxia / Q000188:drug therapy* / Q000209:etiology; D003511:Cyclohexanols / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics; D005600:Fragile X Syndrome / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D008559:Memantine / Q000008:administration & dosage*; D014202:Tremor / Q000188:drug therapy* / Q000209:etiology; D000069470:Venlafaxine Hydrochloride
chemical_list: D003511:Cyclohexanols; D051860:Fragile X Messenger Ribonucleoprotein 1; D008559:Memantine; D000069470:Venlafaxine Hydrochloride; C497683:FMR1 protein, human